Detecting and managing adverse events (AEs) while evaluating potential patient benefit with KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib)

KEYTRUDA Prescribing Information (Great Britain)
KEYTRUDA Prescribing Information (Northern Ireland)
LENVIMA Prescribing Information
[External links]

KEYTRUDA Prescribing Information (Great Britain)
KEYTRUDA Prescribing Information (Northern Ireland)
LENVIMA Prescribing Information
[External links]

Length: 11:28

Dr Clare Green, Consultant Medical Oncologist, describes her experience of using KEYTRUDA + LENVIMA in advanced endometrial cancer through reviewing clinical data and addressing the adverse events portfolio, by sharing a clinical case study.

More information about KEYTRUDA® (pembrolizumab) in endometrial cancer

Supporting documentation

KEYTRUDA® (pembrolizumab)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

LENVIMA® 4 mg hard capsules
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

LENVIMA® 10 mg hard capsules
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet